Resources for patients and caregivers

GRIN Therapeutics has its roots in working with patients, caregivers, and families of people living with developmental and epileptic encephalopathies. Our connections with those living with these conditions continues to inform the design and structure of our clinical development programs. We believe in putting people at the center of everything we do.

How do I get more information and see if my child qualifies for Beeline?

If you are located in the US, you can reach out to InformedDNA, a genetic counseling service that provides genetic counseling, including up to date information about variant characterization, and certain available clinical research opportunities specifically for patients with GRIN-NDD, including the Beeline Trial. This is a pre-screening process, patients will still need to visit the study site for screening to determine eligibility for enrollment.

Globally, the most up to date information on the Beeline Trial will be available on ClinicalTrials.gov under identifier: NCT07224581.

You or your physician may contact clinical trial sites related to the Beeline trial directly to discuss your options and potential eligibility for enrollment. Please note that trial doctors at Beeline study sites make the final decisions about patient enrollment in the trial based upon very specific trial enrollment eligibility requirements.

 

My child doesn’t have seizures, can they still be in your study?

Children who do not have seizures may be eligible for the Beeline Trial. There is a cohort in the study that includes patients who do not have seizures, have too few seizures to qualify for the seizure cohort, or have non-countable seizures. Please note that trial doctors at Beeline study sites make the final decisions about patient enrollment in the trial based upon very specific trial enrollment eligibility requirements.

 

I don’t know my child’s functional consequence (LoF/GoF), how can I find out?

If you are located in the US, you can reach out to InformedDNA, a genetic counseling service that provides genetic counseling, including up to date information about variant characterization, and certain available clinical research opportunities specifically for patients with GRIN-NDD, including the Beeline trial. They can help you understand what is known about your child’s variant and route the variant for testing if it has not yet been tested.

Globally, you can verify the status of your child’s variant on the GRIN Portal.

 

My child has a loss-of-function variant, can they still be in the study?

The Beeline trial is only enrolling patients with GRIN-NDD gain-of-function variants. However, we are aware of the unmet need in the non-gain-of-function community and are working to maximize the impact on the broader GRIN-NDD population through additional studies expected to begin enrollment in the coming months.

 

Where is the Beeline trial being run?

The Beeline trial is a global clinical trial. We anticipate sites being open in North America, Europe, Asia, and Australia. As geographies and trial sites open, the locations will appear on the Beeline clinical trial listing on ClinicalTrials.gov under identifier: NCT07224581.

 

Why is radiprodil targeted for GRIN-NDD patients?

Radiprodil is a targeted, disease-specific potential treatment for GRIN-NDD. As a GluN2B negative allosteric modulator, it modulates the function of the NMDA receptor and targets underlying biology of GRIN-NDD and has the potential to be disease-modifying, or to have an effect on multiple symptoms.

 

What is a placebo-controlled trial and why is it necessary?

A placebo-controlled trial is a type of medical study where some people receive the actual treatment and the others receive a placebo – a substance that looks like the treatment but does not have any active ingredients – so researchers can see if the treatment works better than not receiving it.  Participants do not know which one they are getting to keep the results unbiased.

 

Does this trial require travel to sites?

This study is a hybrid design. It will include some visits to sites as well as some at home participation, including at-home EEGs. While we recognize travel is a challenge for children with GRIN-NDD, trials involving in-person visits with specialists—provide critical advantages in rare disease research. These advantages include improved data quality, patient safety, and increased patient engagement, all of which are essential for generating robust clinical evidence. Travel support, including covering reasonable travel expenses and providing support for travel logistics for your family, will be available for families in the pivotal Phase 3 clinical trial.